Evaluation of the Effects of
Apatinib on the Pharmacokinetics of Tramadol and O-desmethyltramadol
Su-su Bao1#, Peng-fei Tang1#,
Nan-yong Gao2, Xiang-ran Lu1,
Hong-lei Ge1, Guo-xin Hu 2*,
Zhong-xiang Xiao1*
1Affiliated
Yueqing Hospital, Wenzhou Medical University, Wenzhou 325600, Zhejiang,
People’s Republic of China
2School of
Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325000,
Zhejiang, People’s Republic of China
Address correspondence to:
Zhong-xiang Xiao, Affiliated Yueqing Hospital, Wenzhou Medical
University, Wenzhou 325600, Zhejiang, People’s Republic of China. E-mail
addresses: xiangzi198155@163.com
Guo-xin Hu, School of Pharmaceutical Sciences, Wenzhou Medical
University, Wenzhou 325000, Zhejiang, People’s Republic of China. E-mail
addresses: hgx@wmu.edu.cn
#These authors contributed equally to this work
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT :
Clinically, it is very likely that apatinib and tramadol can be used in
combination. In addition, a previous study found that apatinib can
inhibit CYP2D6, CYP2C9, CYP3A4 and CYP2B6, tramadol is mainly
metabolized by CYP2D6. This suggests that there may be an interaction
between apatinib and tramadol.
WHAT THIS STUDY ADDS :
This study determined the effect of apatinib on the pharmacokinetics of
tramadol and o-desmethyl tramadol in rats. The effects and mechanisms of
apatinib on tramadol in human and rat liver microsomes (RLM and HLM) and
recombinant human CYP2D6.1 were identified.
Abstract
Since the combination of anticancer drugs and opioids is very common,
apatinib and tramadol are likely to be used in combination clinically.
Based on this, it is particularly important to explore the effect of
apatinib on the metabolism of tramadol. This study evaluated the effects
of apatinib on the pharmacokinetics of tramadol and its main metabolite
o-desmethyltramadol in SD rats and the inhibitory effects of apatinib on
tramadol in rat liver microsomes (RLMs), human liver microsomes (HLMs)
and recombinant human CYP2D6.1. The samples were determined by
ultra-performance liquid chromatography-tandem mass spectrometry
(UPLC-MS/MS). The in vivo results showed that compared with the control
group, apatinib increased the AUC(0-t),
AUC(0-∞) and Cmax values of tramadol and
O-desmethyltramadol, and decreased the values of VZ/F
and CLz/F. In addition, the MRT(0-t),
MRT(0-∞) values of O-desmethyltramadol were increased.
In vitro, apatinib inhibited the metabolism of tramadol by a mixed way
with IC50 of 1.927µM in RLMs, 2.039µM in HLMs and
15.32µM in CYP2D6.1.
Key words: Apatinib; tramadol; O-desmethyltramadol; Drug Inhibition;
Pharmacokinetics; Metabolism;
Introduction and
Background
Tramadol is a centrally acting, fully synthetic opioid with an atypical
mechanism of action, because it is not only a μ-opioid receptor agonist,
but also a serotonin and norepinephrine reuptake
inhibitor[1]. It was first synthesized
in 1962 and it was made available to the foreign markets under the name
Tramal for pain treatment in 1977[2].
Until 1995, it was approved by the US Food and Drug Administration for
the treatment of moderate to moderately severe pain in
adults[3]. In 2013, tramadol ranked
second in total U.S. opioid market sales, accounting for
14.7%[4]. Typical side effects caused
by opioids include gastrointestinal reactions (nausea, vomiting,
constipation, etc.), itching, dizziness, hypogonadism, sleep
disturbance, inattention, respiratory depression, etc. In addition to
this, there are other effects related to tolerance, dependence, and
addiction[5-8]. Tramadol is generally
considered to be a ”weak opioid” (its agonistic effect on μ-opioid
receptors is only one-fourth to one-tenth of that of morphine), which
makes it mistaken for better
security[3]. However, due to the
inhibition of serotonin and norepinephrine reuptake, tramadol has
additional risks in addition to the side effects of opioids, including:
epilepsy, tachycardia, serotonin syndrome, hypertension, and reports of
mania[9,
10].
The metabolism of tramadol is very complex. At present, 23 different
metabolites (active and inactive) of tramadol have been identified in
humans[2,
11]. Among them, O-desmethyltramadol is
the main active metabolite, and tramadol selectively activates µ opioid
receptors through it. The affinity of O-desmethyltramadol is 700 times
higher than its parent compound tramadol and 5.5 times lower than
morphine[12]. Tramadol is metabolized
to O-desmethyltramadol by CYP2D6, and to N-desmethyltramadol by CYP 3A4
and 2B6. N-desmethyltramadol is pharmacologically
inactive[2,
13]. Therefore, changes in CYP450 will
affect the metabolism of tramadol and the accumulation of metabolites.
Apatinib (Aitan, brand name in China) is a small molecule tyrosine
kinase inhibitor, independently developed by China and approved for the
subsequent-line treatment of advanced gastric or gastroesophageal
junction adenocarcinoma[14]. As one
of the latest oral anti-angiogenic drugs, apatinib has been applied to
various types of malignant tumors, such as breast cancer, non-small cell
carcinoma and epithelial ovarian cancer etc., and has obvious survival
benefits and tolerable
toxicity[14-19]. Cancer and pain are
inseparable. Moderate to severe pain is common in cancer patients,
affecting 70-80% of patients with advanced
disease[20]. Opioids are still the
basic means to control cancer-related pain and are promoted in
international guidelines[21]. It
seems that the combination of anticancer drugs and opioids is very
common. Therefore, it is very likely that apatinib and tramadol can be
combined clinically. In addition, a previous study found that apatinib
can inhibit CYP2D6, CYP2C9, CYP3A4 and
CYP2B6[22], and tramadol is mainly
metabolized by CYP2D6. This suggests there may be an interaction between
apatinib and tramadol.
In this study, in vivo, we determined the effect of apatinib on the
pharmacokinetics of tramadol and o-desmethyltramadol in rats. In vitro,
we identified the effect and mechanism of apatinib on tramadol in human
and rat liver microsomes (RLM and HLM) as well as recombinant human
CYP2D6.1.
2.Materials and Methods
2.1. Chemical and reagents
Tramadol, O-desmethyltramadol, apatinib and midazolam (used as internal
standard, IS) were bought from Shanghai Canspec Scientific & Technology
Co., Ltd. LC–MS grade acetonitrile (ACN) and methanol were purchased
from Merck (Darmstadt, Germany). Formic acid of HPLC grade (FA, purity
99.9%) was obtained from J&K scientific Ltd. (Shanghai, China). The
reduced nicotinamide adenine dinucleotide phosphate (NADPH) was
purchased from Roche Pharmaceutical Ltd. (Basel, Switzerland).
Carboxymethylcellulose sodium salt (CMC-Na) was from Sigma-Aldrich
Company (Shanghai, China). Pooled RLM and HLM were bought from Corning
Life Sciences Co., Ltd. Recombinant human CYP2D6.1 and cytochrome b5
were kind gifts from Beijing Hospital (Beijing, China).
2.2. Equipment and operation conditions
The concentration of tramadol and
O-desmethyltramadol was determined by ultra-performance liquid
chromatography-tandem mass spectrometry (UPLC-MS/MS). Mass spectrometer
contained an Acquity UPLC XEVO TQD triple quadrupole (Waters Corp.,
Milford, MA) and an electrospray ionization source. The chromatographic
separation was performed on a Waters ACQUITY UPLC BEH C18 column (2.1×50
mm, 1.7μm, Waters Corp.) at 40°C. The transitions were m/z 264.2→58.0
for tramadol, m/z 250.2→58.2 for O-desmethyltramadol, m/z 326.1→291.1
for IS. The mobile phase consisted of solvent A (0.1% formic acid) and
solvent B (ACN) with gradient elution at a flow rate of 0.4 mL/min,
total run time was 2 min. A gradient elution program was as follows:
0–1.4 min, 60%–10% A, 1.4–2.6 min, 10%–60% A.
2.3. In vitro experiments
The 200µL incubation system contained 1.6µL apatinib, 3.0µL tramadol,
5µL Rat liver microsomes (RLM) or Human liver microsomes (HLM) or 5µL
CYPD6.1 (along with 3.7µL b5), and10µL NADPH (1mM), and180.4µL 1M
potassium phosphate buffer (PBS)for HLM and RLM, 176.7µL PBS for
CYP2D6.1. In the experiment of IC50 determination, the concentration of
apatinib was designed at 0.01, 0.1, 1, 10, 50 and 100µM, while that of
tramadol was 80µM for RLM, 50 µM for HLM, 40 µM for CYP2D6.1, which were
close to their Km value correspondingly. In the experiment of the
inhibitory effect of apatinib on tramadol, the concentration gradient of
apatinib (0-32µM) and tramadol (10-160µM) was set according to the IC50
value and the Km value. The incubation system was carried out at 37°C,
and after incubating for 30 minutes, it was cooled to -80°C. Then 400 µL
ACN and 20 µL IS (20ng mL-1) were added to the
mixture. After vortex mixing for 2 minutes and high-speed centrifugation
at 13000 rpm for 10 minutes, the supernatant was taken for testing.
2.3. In Vivo Experiments
12 male Sprague–Dawley (SD) rats purchased from the Shanghai Animal
Experimental Center were randomly divided into 2 groups (n=6): group A
was apatinib group (taking apatinib with tramadol), group B was the
control group (taking tramadol alone). Before the formal experiment, the
12 rats were fasted for 12 hours. At the beginning of the experiment,
the group A was given 40mg kg-1 apatinib orally, and
the group B was given the same volume of 0.5% CMC-Na. After 30 minutes,
both groups were given 20 mg kg-1 tramadol. The time
points of blood collection from the tail vein of rats were 0.083, 0.25,
0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after
administration of tramadol.
The above blood was centrifuged at 13,000 rpm for 10 minutes to obtain
the required plasma. 100µL of the collected plasma was taken and mixed
with 20µL IS (300ng mL-1) and 200µL ACN in a 1.5mL
centrifuge tube. After being vortexed for 2 minutes and centrifuged for
10 minutes, the supernatant was diluted with pure water (1:1) for
UPLC-MS/MS analysis.
2.4. Statistical Analysis
IC50 and Lineweaver-Burk Plot are calculated by GraphPad
Prism 5.0. The average concentration-time curve is drawn by Origin 8.0.
The pharmacokinetic parameters were evaluated by DAS software (version
3.0), using non-compartmental analysis. The statistical analysis of all
data is expressed as mean ± standard deviation and analyzed by SPSS
19.0. P<0.05 represents statistical significance.
3.Results
3.1. UPLC-MS/MS
The correlation coefficients of the calibration curves of tramadol and
o-desmethyltramadol were both greater than 0.99. Tramadol is used in a
concentration range of 0.25 to 500 ng mL-1, and
o-desmethyltramadol is used in a concentration range of 1 to 1000 ng
mL-1. The chromatograms of tramadol,
O-desmethyltramadol and IS under different conditions are shown in
Figure 1.
3.2. Effects of apatinib on the metabolism of tramadol in vitro
The IC50 curve and Lineweaver-Burk Plot of apatinib on
tramadol in HLM, RLM and CYP2D6.1 are
shown in Figure 2 and Figure 3, respectively, and the corresponding
values are shown in Table 1.
According to Table 1, The IC50 values of RLM and HLM are
very close (Table 1). The inhibitory strength of apatinib on tramadol is
greater in RLM and HLM than in CYP2D6.1. The results indicate that
apatinib inhibits tramadol in a mixed way.
3.3. Effects of apatinib on the metabolism of tramadol in vivo
The average plasma concentration-time curves of tramadol and
O-desmethyltramadol and their corresponding pharmacokinetic parameters
are shown in Figure 4 and Table 2 and 3.
Compared with group B (control
group), the AUC(0-t), AUC(0-∞) and
Cmax values of tramadol and O-desmethyltramadol
increased, while VZ/F and CLz/F decreased. In addition,
the MRT(0-t), MRT(0-∞) values of
O-desmethyltramadol increased. Other parameters have no significant
difference.
4. Discussion
Tramadol is mainly metabolized by CYP2D6, CYP3A4 and CYP2B6. Since the
phase I metabolic reaction mediated by CYP450 is slower than the phase
II binding reaction, they become the rate-limiter for the overall
metabolic disposal of CYP substrate
drugs[4]. CYP enzymes are easily
induced and inhibited by other substrates, which means that the plasma
concentration and tissue distribution of tramadol and its main
metabolite o-desmethyltramadol may be affected by drugs that affect the
activities of CYP2D6, CYP3A4 and CYP2B6. Since apatinib is metabolized
by CYP3A4/5, CYP2D6, CYP2C9 and
CYP2E1[23], sharing two CYP metabolic
pathways with tramadol, and the fact that tramadol and apatinib are
likely to be combined clinically, whether apatinib affects the
metabolism of tramadol is worth studying.
The results of in vivo experiments show that apatinib does influence the
metabolism of tramadol. Compared with the control group, the AUC(0-t), AUC (0-∞) and
Cmax of tramadol increased, Vz/F and CLz/F decreased,
which proves that apatinib inhibits the metabolism of tramadol in rats,
increasing the side effects of tramadol. The inhibitory effect of
tramadol on the neuronal reuptake of norepinephrine and 5-HT increases
its side effect compared with other
opioids[24]. This in vivo result
corresponds to the subsequent in vitro result. Apatinib strongly
inhibited the metabolism of tramadol by a mixed way with
IC50 <5 µM in RLMs. The results in HLMs are
close to those in RLMs, indicating that the effects of apatinib on the
metabolism of tramadol in rat can be analogized to humans to a certain
extent. Studies have pointed out that tramadol is metabolized much
faster in animals than in humans: 1% and 25-30% of the oral dose are
excreted in urine as prototypes
respectively[2,
25]. This also implies that when
apatinib and tramadol are used in combination in humans, the
accumulation of tramadol is more serious than in rats.
Although CYP2D6 only accounts for ∼ 2-4% of all liver CYP enzymes, it
metabolizes about 25% of clinically used drugs, and about 80% of
tramadol is metabolized by CYP2D6[4,
26-28]. Based on this, we studied the
potential inhibitory effects of apatinib on tramadol in CYP2D6.1.
Apatinib inhibits tramadol by a mixed way in CYP2D6.1, suggesting the
complexity of the inhibition way. The inhibitory intensity of apatinib
in 2D6.1 is much smaller than that of RLM and HLM, the reason may be
that the inhibition of tramadol by apatinib in vitro is not only through
CYP2D6. Studies have shown that apatinib can strongly inhibit CYP3A4 and
CYP2B6[22] while the N-demethylation
process of tramadol is through these two
enzymes[29]. Therefore, apatinib may
also inhibit the metabolism of tramadol through CYP3A4 and CYP2B6.
In addition, compared with the control group, the exposure of
O-desmethyltramadol to AUC (0-t), AUC(0-∞), MRT(0-t),
MRT(0-∞) and Cmax was increased
significantly, This may be because apatinib significantly reduced
tramadol’s first pass elimination,which greatly increased the amount of
absorption. Besides, O-desmethyltramadol will subsequently be
metabolized into N,O-didesmethyl-tramadol through CYP3A4 and
CYP2B6[30], and this process may be
hindered by apatinib[22]. Since
O-desmethyltramadol is the main active metabolite, and its affinity is
700 times higher than that of its parent compound, exaggerated effects
or even opioid intoxication may occur.
In conclusion, based on our research results, apatinib can enhance the
analgesic effect of o-desmethyltramadol, but also greatly increase the
toxic and side effects caused by the accumulation of tramadol and
o-desmethyltramadol. In order to avoid the risk of greatly increased
adverse reactions, we do not recommend simultaneous administration of
apatinib and tramadol clinically. Due to the high probability of
combined application of apatinib and tramadol in cancer patients, our
study provides a contribution to the rational use of drugs in this
regard.
5.Acknowledgments
This work was supported by National Key Research and Development Program
of China (2020YFC2008301), and National Natural Science Foundation of
China (NSFC 81973397).
6. Conflict of interest
statement
The authors report no conflicts of interest in this work.
7. Data availability
statement
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
[1] J. Barbosa, J. Faria, O.
Queiros, R. Moreira, F. Carvalho, R.J. Dinis-Oliveira, Comparative
metabolism of tramadol and tapentadol: a toxicological perspective, Drug
metabolism reviews, 48 (2016) 577-592.
[2] S. Grond, A. Sablotzki,
Clinical pharmacology of tramadol, Clinical pharmacokinetics, 43 (2004)
879-923.
[3] S. Hassamal, K. Miotto, W.
Dale, I. Danovitch, Tramadol: Understanding the Risk of Serotonin
Syndrome and Seizures, The American journal of medicine, 131 (2018) 1382
e1381-1382 e1386.
[4] K. Miotto, A.K. Cho, M.A.
Khalil, K. Blanco, J.D. Sasaki, R. Rawson, Trends in Tramadol:
Pharmacology, Metabolism, and Misuse, Anesthesia and analgesia, 124
(2017) 44-51.
[5] L. Ventura, F. Carvalho, R.J.
Dinis-Oliveira, Opioids in the Frame of New Psychoactive Substances
Network: A Complex Pharmacological and Toxicological Issue, Current
molecular pharmacology, 11 (2018) 97-108.
[6] T. Gunther, P. Dasgupta, A.
Mann, E. Miess, A. Kliewer, S. Fritzwanker, R. Steinborn, S. Schulz,
Targeting multiple opioid receptors - improved analgesics with reduced
side effects?, British journal of pharmacology, 175 (2018) 2857-2868.
[7] G. Burgess, D. Williams, The
discovery and development of analgesics: new mechanisms, new modalities,
The Journal of clinical investigation, 120 (2010) 3753-3759.
[8] L. Manchikanti, B. Fellows, H.
Ailinani, V. Pampati, Therapeutic use, abuse, and nonmedical use of
opioids: a ten-year perspective, Pain physician, 13 (2010) 401-435.
[9] B.D. Beakley, A.M. Kaye, A.D.
Kaye, Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A
Review, Pain physician, 18 (2015) 395-400.
[10] W. Reimann, F. Schneider,
Induction of 5-hydroxytryptamine release by tramadol, fenfluramine and
reserpine, European journal of pharmacology, 349 (1998) 199-203.
[11] W.N. Wu, L.A. McKown, S.
Liao, Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride)
in humans: API-MS and MS/MS characterization of metabolites,
Xenobiotica; the fate of foreign compounds in biological systems, 32
(2002) 411-425.
[12] C. Gillen, M. Haurand, D.J.
Kobelt, S. Wnendt, Affinity, potency and efficacy of tramadol and its
metabolites at the cloned human mu-opioid receptor,
Naunyn-Schmiedeberg’s archives of pharmacology, 362 (2000) 116-121.
[13] L. Gong, U.M. Stamer, M.V.
Tzvetkov, R.B. Altman, T.E. Klein, PharmGKB summary: tramadol pathway,
Pharmacogenetics and genomics, 24 (2014) 374-380.
[14] X. Hu, J. Cao, W. Hu, C. Wu,
Y. Pan, L. Cai, Z. Tong, S. Wang, J. Li, Z. Wang, B. Wang, X. Chen, H.
Yu, Multicenter phase II study of apatinib in non-triple-negative
metastatic breast cancer, BMC cancer, 14 (2014) 820.
[15] J. Huang, Q. Fan, P. Lu, J.
Ying, C. Ma, W. Liu, Y. Liu, F. Tan, Y. Sun, Icotinib in Patients with
Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR
Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter
Phase 2 Study, Journal of thoracic oncology : official publication of
the International Association for the Study of Lung Cancer, 11 (2016)
910-917.
[16] W. Lu, X.L. Jin, C. Yang, P.
Du, F.Q. Jiang, J.P. Ma, J. Yang, P. Xie, Z. Zhang, Comparison of
efficacy between TACE combined with apatinib and TACE alone in the
treatment of intermediate and advanced hepatocellular carcinoma: A
single-center randomized controlled trial, Cancer biology & therapy, 18
(2017) 433-438.
[17] M. Miao, G. Deng, S. Luo, J.
Zhou, L. Chen, J. Yang, J. He, J. Li, J. Yao, S. Tan, J. Tang, A phase
II study of apatinib in patients with recurrent epithelial ovarian
cancer, Gynecologic oncology, 148 (2018) 286-290.
[18] C.J. Langer, T. Mok, P.E.
Postmus, Targeted agents in the third-/fourth-line treatment of patients
with advanced (stage III/IV) non-small cell lung cancer (NSCLC), Cancer
treatment reviews, 39 (2013) 252-260.
[19] G. Zhang, S. Gong, L. Pang,
L. Hou, W. He, Efficacy and Safety of Apatinib Treatment for Advanced
Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An
Open-Label Phase II Prospective Study, Frontiers in oncology, 11 (2021)
659217.
[20] A. Caraceni, G. Hanks, S.
Kaasa, M.I. Bennett, C. Brunelli, N. Cherny, O. Dale, F. De Conno, M.
Fallon, M. Hanna, D.F. Haugen, G. Juhl, S. King, P. Klepstad, E.A.
Laugsand, M. Maltoni, S. Mercadante, M. Nabal, A. Pigni, L. Radbruch, C.
Reid, P. Sjogren, P.C. Stone, D. Tassinari, G. Zeppetella, C. European
Palliative Care Research, C. European Association for Palliative, Use of
opioid analgesics in the treatment of cancer pain: evidence-based
recommendations from the EAPC, The Lancet. Oncology, 13 (2012) e58-68.
[21] S. Edler-Buggy, J.
Birtwistle, Y. ElMokhallalati, K. Kindl, P. Good, M.I. Bennett, Regular
dosing compared with as-needed dosing of opioids for management of
chronic cancer pain: systematic review and meta-analysis, Pain, 161
(2020) 703-712.
[22] S.S. Bao, J. Wen, X. Zheng,
Q. Zhou, G.E. Qu, M.J. Chen, G.X. Hu, Evaluation of the inhibition
effects of apatinib on human and rat cytochrome P450, Toxicology
letters, 297 (2018) 1-7.
[23] J. Ding, X. Chen, Z. Gao, X.
Dai, L. Li, C. Xie, H. Jiang, L. Zhang, D. Zhong, Metabolism and
pharmacokinetics of novel selective vascular endothelial growth factor
receptor-2 inhibitor apatinib in humans, Drug metabolism and
disposition: the biological fate of chemicals, 41 (2013) 1195-1210.
[24] K. Minami, Y. Uezono, Y.
Ueta, Pharmacological aspects of the effects of tramadol on G-protein
coupled receptors, Journal of pharmacological sciences, 103 (2007)
253-260.
[25] W. Lintz, S. Erlacin, E.
Frankus, H. Uragg, [Biotransformation of tramadol in man and animal
(author’s transl)], Arzneimittel-Forschung, 31 (1981) 1932-1943.
[26] S.F. Zhou, Polymorphism of
human cytochrome P450 2D6 and its clinical significance: Part I,
Clinical pharmacokinetics, 48 (2009) 689-723.
[27] S.F. Zhou, Polymorphism of
human cytochrome P450 2D6 and its clinical significance: part II,
Clinical pharmacokinetics, 48 (2009) 761-804.
[28] T.B. Jin, L.F. Ma, J.Y.
Zhang, D.Y. Yuan, Q. Sun, T.Y. Zong, T.T. Geng, Y.L. Cui, L.L. Kang, C.
Chen, Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in
the Tibetan population, Gene, 527 (2013) 360-365.
[29] J. Kirchheiner, J.T. Keulen,
S. Bauer, I. Roots, J. Brockmoller, Effects of the CYP2D6 gene
duplication on the pharmacokinetics and pharmacodynamics of tramadol,
Journal of clinical psychopharmacology, 28 (2008) 78-83.
[30] V. Subrahmanyam, A.B.
Renwick, D.G. Walters, P.J. Young, R.J. Price, A.P. Tonelli, B.G. Lake,
Identification of cytochrome P-450 isoforms responsible for cis-tramadol
metabolism in human liver microsomes, Drug metabolism and disposition:
the biological fate of chemicals, 29 (2001) 1146-1155.
Table.1. The IC50 values and inhibitory effects of apatinib on
tramadol in HLMs, RLMs and CYP2D6.1